IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq: XBIT). Investors who purchased or otherwise acquired shares between April 15, 2015 and November 23, 2015, inclusive (the “Class Period”), are encouraged to contact the firm prior to the February 1, 2016 lead plaintiff motion deadline.
If you purchased shares of XBiotech during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by email at joon@khanglaw.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company issued materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; and (3) XBiotech did not adequately sample patients to accommodate data loss.
If you purchased shares of XBiotech during the Class Period, you have until February 1, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: 949-419-3834, or by email at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.